XLO News and Press, Xilio Therapeutics Inc. From 01/31/24

WALTHAM, Mass., Jan. 31, 2024 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced that René Russo, Pharm.D., president and chief ...

Dosing XTX301 at 45 ug/kg once every three weeks (dose level 3) in ongoing Phase 1 trial, nearly 100x the maximum tolerated dose of rhIL-12, with no dose-limiting toxicities observed to date Initiated patient dosing in Phase 1/2 trial for XTX101, a tumor-activated, Fc-enhanced anti-CTLA...

Phase 1 combination dose escalation expected to support planned Phase 2 trial in microsatellite stable colorectal cancer (MSS CRC) Updated Phase 1 monotherapy data for XTX101 at the recommended Phase 2 dose (RP2D) continues to demonstrate minimal treatment-related adverse events, consis...

2023-11-10 07:28:58 ET Xilio Therapeutics press release ( NASDAQ: XLO ): Q3 GAAP EPS of -$0.61. Cash and cash equivalents were $59.8M as of September 30, 2023, compared to $120.4M as of December 31, 2022. For further details see: Xilio Therapeutics GAAP EPS of -$...

Demonstrated initial clinical validation of tumor-selective activation technology for both XTX101, a tumor-activated, Fc-enhanced anti-CTLA-4, and XTX202, a tumor-activated, beta-gamma IL-2 On track to activate trial sites for XTX101 dose escalation in combination with atezolizumab unde...

Evotec SE (EVO) is expected to report $-0.03 for Q3 2023 Amplifon (AMFPF) is expected to report for Q3 2023 Compass Therapeutics Inc. (CMPX) is expected to report $-0.11 for Q3 2023 Astronics Corp. - Class B (ATROB) is expected to report for Q4 2023 Charge Enterprises Inc. (CRGE) ...

Xilio Therapeutics Inc. (XLO) is expected to report $-0.76 for Q3 2023

2023-11-06 12:51:18 ET Gainers: MSP Recovery ( LIFW ) +458% . Bluegreen Vacations Holding Corporation ( BVH ) +106% . Tenon Medical ( TNON ) +72% . Cano Health ( CANO ) +43% . Cheetah Net Supply Chain Service ( CTNT ) +36% . ...

Initial evidence of dose-dependent disease control rate with 50% disease control rate at higher doses (≥2.8 mg/kg) and 31% disease control rate across all dose levels in a range of solid tumor types, including cold tumors Treatment-related adverse events primarily Grade 1-2 at do...

WALTHAM, Mass., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced that it will host an investor conference call and we...